- Home
- NAUT vs IMAB Comparison
NAUT vs IMAB Comparison
Compare NAUT & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAUT
- IMAB
- Stock Information
- Founded
- NAUT 2016
- IMAB 2014
- Country
- NAUT United States
- IMAB United States
- Employees
- NAUT N/A
- IMAB N/A
- Industry
- NAUT Biotechnology: Laboratory Analytical Instruments
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- NAUT Industrials
- IMAB Health Care
- Exchange
- NAUT Nasdaq
- IMAB Nasdaq
- Market Cap
- NAUT 91.5M
- IMAB 200.9M
- IPO Year
- NAUT N/A
- IMAB 2020
- Fundamental
- Price
- NAUT $0.69
- IMAB $2.45
- Analyst Decision
- NAUT Hold
- IMAB Strong Buy
- Analyst Count
- NAUT 2
- IMAB 2
- Target Price
- NAUT $3.88
- IMAB $6.00
- AVG Volume (30 Days)
- NAUT 553.0K
- IMAB 1.2M
- Earning Date
- NAUT 07-29-2025
- IMAB 05-15-2025
- Dividend Yield
- NAUT N/A
- IMAB N/A
- EPS Growth
- NAUT N/A
- IMAB N/A
- EPS
- NAUT N/A
- IMAB N/A
- Revenue
- NAUT N/A
- IMAB N/A
- Revenue This Year
- NAUT N/A
- IMAB N/A
- Revenue Next Year
- NAUT N/A
- IMAB N/A
- P/E Ratio
- NAUT N/A
- IMAB N/A
- Revenue Growth
- NAUT N/A
- IMAB N/A
- 52 Week Low
- NAUT $0.66
- IMAB $0.60
- 52 Week High
- NAUT $3.09
- IMAB $3.08
- Technical
- Relative Strength Index (RSI)
- NAUT 43.84
- IMAB 50.05
- Support Level
- NAUT $0.69
- IMAB $2.35
- Resistance Level
- NAUT $0.85
- IMAB $2.59
- Average True Range (ATR)
- NAUT 0.06
- IMAB 0.35
- MACD
- NAUT 0.00
- IMAB -0.06
- Stochastic Oscillator
- NAUT 8.70
- IMAB 1.86
About NAUT Nautilus Biotechnolgy Inc.
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. Company's products includes: Proteome Analysis System, Reagent Kits, Software and analysis.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).